Tumor immunotherapy antibody fusion protein BY24.3 IPR: Dual-targeted fusion protein targeting PD1 or PD-L1 and targeting the VEGF family and its use (Patent Application No. 201710905683.9, PCT/CN2018/10674),The effectiveness of PD1/PD-L1 combination anti-angiogenic therapy may be based on the fact that: Improve the efficacy of PD1/PD-L1 monoclonal antibody by blocking the immunosuppressive effects of VEGF and promoting T-cell infiltration in tumour tissue. Drugs acting on the VEGF target effectively "modulate" the normalisation of tumour neovascularisation and improve the immune "desertification" of tumour tissue due to abnormal neovascularisation.

Intellectual property of tumour immunotherapeutic antibody fusion protein BY24.26: multi-targeted fusion protein blocking vascular endothelial cell growth and activating T cells and contained drug compositions (Patent Application No. 201910023522.6, International Patent Application No. PCT/CN2020/071213)

Erythropoietin (EPO) is also a colony-stimulating factor, which promotes the expansion and differentiation of bone marrow erythroid colony-forming units, cooperates with other cell growth factors to promote cell proliferation and differentiation, inhibits apoptosis and increases the number of red blood cells. After the cDNA of EPO was successfully cloned in 1985, rhEPO has been widely used in the treatment of various anaemic diseases. Currently, the indications for rhEPO drugs in China are mainly for the treatment of chronic kidney disease (CKD) and chemotherapy-related anemia (CRA). It has become one of the most important supportive tools in the treatment of anaemia.

This product is an upgraded product of short-acting recombinant granulocyte stimulating factor and long-acting PEGylated granulocyte stimulating factor, which will be able to encroach on the market share of both short-acting and long-acting granulocyte stimulating factors. It is planned to produce 5 million injections per year, with a construction period of 3 years. After the project reaches production, it can achieve an annual sales revenue of RMB 3 billion, complete the annual tax revenue of over RMB 600 million, and arrange employment of more than 160 people with various types of technical labour.

1. To promote the increase of neutrophil number during bone marrow transplantation.2. Prevention of neutropenia caused by anti-tumor chemotherapy drugs and shortening the duration of neutropenia; Solid Tumor;Acute Lymphoblastic Leukemia.